Phase II study of high-dose [131i]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma

Journal of Clinical Oncology

Volumn 27, Issue 25, 2009, Pages 4162-4168

  Gonias, Sara ^a   Goldsby, Robert ^a   Matthay, Katherine K ^a   Hawkins, Randall ^a   Price, David ^a   Huberty, John ^a   Damon, Lloyd ^a   Linker, Charles ^a   Sznewajs, Aimee ^a   Shiboski, Steve ^a   Fitzgerald, Paul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CHROMOGRANIN A; METADRENALIN; NIFEDIPINE; PREDNISONE; (3 IODOBENZYL)GUANIDINE; CATECHOLAMINE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CANCER GROWTH; CANCER SURVIVAL; CATECHOLAMINE URINE LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FEVER; HUMAN; HYPERTENSION; HYPOGONADISM; INFECTIOUS PNEUMONIA; LUNG EMBOLISM; MALE; METASTASIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY INSUFFICIENCY; PARAGANGLIOMA; PHASE 2 CLINICAL TRIAL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADRENAL TUMOR; DISEASE FREE SURVIVAL; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RADIATION RESPONSE; RISK ASSESSMENT; TIME; TREATMENT OUTCOME; URINE;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; CATECHOLAMINES; CHILD; CHROMOGRANIN A; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; IODINE RADIOISOTOPES; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 70249133742     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.3496     Document Type: Article

References (19)

1. Fitzgerald PA, Goldsby RE, Huberty JP, et al: Malignant pheochromocytomas and paragangliomas: A phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 1073:465-490, 2006
2. Ahlman H: Malignant pheochromocytoma: State of the field with future projections. Ann N Y Acad Sci 1073:449-464, 2006
3. Safford SD, Coleman RE, Gockerman JP, et al: Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134:956-962, 2003; discussion 962-963
4. Rose B, Matthay KK, Price D, et al: High-dose 131I- metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98:239-248, 2003
5. Matthay KK, Panina C, Huberty J, et al: Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 42: 1713-1721, 2001
6. Matthay KK, Tan JC, Villablanca JG, et al: Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approach to Neuroblastoma Therapy Consortium Study. J Clin Oncol 24:500-506, 2006
7. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
8. Loh KC, Fitzgerald PA, Matthay KK, et al: The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients. J Endocrinol Invest 20:648-658, 1997
9. Averbuch SD, Steakley CS, Young RC, et al: Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109:267-273, 1988
10. Huang H, Abraham J, Hung E, et al: Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: Recommendation from a 22-year follow-up of 18 patients. Cancer 113:2020-2028, 2008
11. Joshua AM, Ezzat S, Asa SL, et al: Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 94:5-9, 2009
12. Karagiannis A, Mikhailidis DP, Athyros VG, et al: Pheochromocytoma: An update on genetics and management. Endocr Relat Cancer 14:935-956, 2007
13. Howard JP, Maris JM, Kersun LS, et al: Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 44:232-239, 2005
14. Cornelissen R, Senan S, Antonisse IE, et al: Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma. Radiat Oncol 2:2, 2007
15. Winter C, Schmidt-Mutter C, Cuny R, et al: Fatal form of phaeochromocytoma presenting as acute pyelonephritis. Eur J Anaesthesiol 18:548-553, 2001
16. Feldman JM: Adult respiratory distress syndrome in a pregnant patient with a pheochromocytoma. J Surg Oncol 29:5-7, 1985
17. Spencer E, Pycock C, Lytle J: Phaeochromocytoma presenting as acute circulatory collapse and abdominal pain. Intensive Care Med 19:356-357, 1993
18. Weiss B, Vora A, Huberty J, et al: Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol 25:543-547, 2003
19. Samaan NA, Hickey RC, Shutts PE: Diagnosis, localization, and management of pheochromocytoma: Pitfalls and follow-up in 41 patients. Cancer 62:2451-2460, 1988